Gedeon Richter
Biosimilar developer, Hungary. 4 development products across 4 molecules: denosumab, teriparatide, tocilizumab, ustekinumab.
First approval in the Atlas: Jan 2017, Terrosa, teriparatide (EMA)
FDAproducts approved1
EMAproducts approved4
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Denosumab | Enoby / Xtrenbo / Junod / Yaxwer RGB-14 | Sep 2025 | Jun 2025 | · | · | · | · |
| Teriparatide | Terrosa / Movymia RGB-10 | · | Jan 2017 | · | · | · | · |
| Tocilizumab | Tuyory RGB-19 | · | Apr 2026 | · | · | · | · |
| Ustekinumab | Usymro | · | Aug 2025 | · | · | · | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Gedeon Richter is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Follitropin alfa | Bemfola | EMA | Gedeon Richter Plc. | Mar 2014 | Finox Biotech |
| Follitropin alfa | Bemfola | EDE | Gedeon Richter Plc., Hungary | Sep 2016 | Finox Biotech |
Chronology
- EMAJan 2017Terrosa, teriparatide
- EMAJan 2017Movymia, teriparatide
- EMAJun 2025Junod, denosumab
- EMAJun 2025Yaxwer, denosumab
- EMAAug 2025Usymro, ustekinumab
- FDASep 2025Enoby, denosumab
- FDASep 2025Xtrenbo, denosumab
- EMAApr 2026Tuyory, tocilizumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.